Alzheimer's Clinical Trials in Baltimore
View 19 new treatments for Alzheimer's in Baltimore, MD near me. Every day, Power helps hundreds of Alzheimer's patients connect with leading medical research.Psilocybin for Depression in Alzheimer's
Research Clinic, Baltimore + 1 more
This trial tests if psilocybin, a substance from certain mushrooms, can safely improve depression and quality of life in people with early Alzheimer's or Mild Cognitive Impairment. It works by changing brain activity related to mood. Psilocybin has been studied for its potential to reduce depression and anxiety, particularly in patients with life-threatening conditions.Show More
Verified
No Placebo Trial
Trazodone for Early Alzheimer's Disease
Research Clinic, Baltimore + 1 more
To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).Show More
Verified
Electrical Stimulation for Learning and Memory in Alzheimer's and Primary Progressive Aphasia
Research Clinic, Baltimore + 1 more
This trial tests a new treatment for Alzheimer's patients using a gentle electrical brain stimulation combined with memory exercises. It aims to help those who struggle with memory or language by improving brain cell connections. Transcutaneous electrical nerve stimulation (TENS) has shown positive effects on memory, verbal fluency, and affective behavior in Alzheimer's patients in previous studies.Show More
Verified
No Placebo Trial
AVP-786 for Agitation in Alzheimer's Disease
Avanir Clinic, Glen Burnie + 1 more
This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Remternetug for Alzheimer's Disease
Eli Lilly Clinic, Baltimore + 1 more
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.Show More
Escitalopram for Agitation in Alzheimer's Disease
Research Clinic, Baltimore + 3 more
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
Donanemab for Alzheimer's Disease
Eli Lilly Clinic, Columbia + 3 more
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.Show More
AVP-786 for Agitation in Alzheimer's Disease
Avanir Clinic, Easton + 1 more
This trial is testing a medication called AVP-786 on individuals who have taken part in previous studies. The goal is to see if this medication can help with their conditions over time.Show More
No Placebo Trial
Levetiracetam for Alzheimer's Disease
Research Clinic, Bethesda + 1 more
Patients with Alzheimer's disease (AD) are increasingly recognized to have seizures in addition to cognitive decline. Seizures may contribute to memory problems as well as other symptoms common in AD like agitation, depression, or apathy. These symptoms are collectively called neuro-psychiatric symptoms. Studies of magnetic resonance imaging (MRI) in patients with AD have suggested that injury to certain parts of the brain can cause these neuro-psychiatric symptoms. Based on this evidence, the investigators hypothesize that seizures can also cause neuro-psychiatric symptoms in patients with AD and may be related to the injury seen on MRI. The current study will follow participants for 1 year and will involve participants with AD who also have neuro-psychiatric symptoms. Participants will be examined with three brain wave studies to assess for seizure-like activity. Participants with seizure-like activity will all receive levetiracetam for 1 year. All participants will have their neuro-psychiatric symptoms, cognitive abilities, quality of life, and AD severity assessed throughout the year. The investigators plan to determine if levetiracetam changes the severity of the participants' neuro-psychiatric symptoms compared to their baseline as well as compared to participants without seizure-like activity. 65 participants will need to be recruited to test the study hypotheses. The study will take place at Walter Reed National Military Medical Center.Show More
No Placebo Trial
THC-Based Medication for Agitation in Alzheimer's
IGC Clinic, Olney + 5 more
This trial tests a natural THC-based medicine called IGC-AD1, given in small doses regularly. It targets people aged 60 and above with Alzheimer's-related dementia who have been experiencing agitation. The THC in the medicine helps reduce agitation by interacting with brain signals. The most recent trial reported significant improvement in agitation using nabilone.Show More
Frequently Asked Questions
How much do alzheimer's clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do alzheimer's clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across alzheimers trials in Baltimore, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for alzheimers patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.
Where in Baltimore is research being conducted for alzheimer's?
Prominent hospitals in Baltimore conducting Alzheimer's clinical trials include Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine. Approximately 4 trials are ongoing as of 2023.
What promising new drugs are being tested?
In Baltimore, Alzheimer's research is focusing on treatments like Radiopharmaceuticals and Electrical Stimulation. Notable individual interventions being studied include Amyvid, Escitalopram, and IGC-AD1.